

Elafin(human)

Cat. No.:	HY-P5459
Molecular Formula:	C ₂₅₄ H ₄₁₆ N ₇₂ O ₇₅ S ₁₀
Molecular Weight:	5999.11
Sequence:	Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly-Ser-Cys-Pro-Ile-Ile-Leu-Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-Cys-Pro-Gly-Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys-Phe-Val-Pro-Gln (Disulfide bridge:Cys16-Cys45, Cys23- Cys49, Cys32- Cys44, Cys38-Cys53)
Sequence Shortening:	AQEPVKGPVSTKPGSCPIILIRCAMLNPPNRCLKDTCPIKKCEGSCGMACFVPQ (Disulfide bridge:Cys16- Cys45, Cys23- Cys49, Cys32- Cys44, Cys38-Cys53)
Target:	Bacterial; Elastase
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Elafin, also known as elafin-specific inhibitor (ESI) or skin anti-leucoprotease (SKALP), is a low molecular weight inhibitor of human neutrophil elastase (HNE) and proteinase 3 in lung. Elafin is antibiotic against <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> ^{[1][2][3]} .
--------------------	---

REFERENCES

- [1]. A J Simpson, et al. Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS Lett. 1999 Jun 11;452(3):309-13.
- [2]. Sophie Paczesny, et al. Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin. Sci Transl Med. 2010 Jan 6;2(13):13ra2.
- [3]. Lee Shaw, et al. Therapeutic potential of human elafin. Biochem Soc Trans. 2011 Oct;39(5):1450-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA